Patrick Alexandre News Today

Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares,...

Focusing on regulatory filings and accelerating U.S. commercialization efforts Contract of up to $155 million with BARDA for U.S. stockpiling continues to advance Dijon, France February 6, 2024...

Dijon, France, February 1, 2024 -- 18:15 CET - Crossject , a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a conference call on its commercial...

Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free...

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®  Crossject expanding market access activities in preparation for filing for marketing...

Press ReleaseCrossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®Crossject expanding market access activities in preparation f...

Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner, allows Crossject to benefit from strong...

Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner,...

Press Release Crossject reports financial results and business highlights for first half of 2023   Strong progress in bringing drugs for use in emergency situations towards the market ...

Press Release Crossject reports financial results and business highlights for first half of 2023   Strong progress in bringing drugs for use in...